Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1983 Apr;47(4):511–515. doi: 10.1038/bjc.1983.81

Variation of receptor status in cancer of the breast.

R N Harland, D M Barnes, A Howell, G G Ribeiro, J Taylor, R A Sellwood
PMCID: PMC2011332  PMID: 6682673

Abstract

One hundred and nineteen patients with breast cancer had 2 or more lesions removed for oestrogen (REc) or progesterone receptor (RPc) assay, either synchronously (on 38 occasions) or after an interval (on 91 occasions). In all but 7 both receptors were assayed for each lesion. The assays did not agree on the presence or absence of REc alone, RPc alone or the combination of both receptors in 11, 13 and 16% respectively of the synchronous samples, compared with 23, 30 and 43% of the asynchronous samples. The differences between the synchronous and asynchronous samples were significant for the combined receptors (P = 0.007) but not for REc (P = 0.176) or RPc alone (P = 0.077). Variation between asynchronous biopsies was greater when the earlier lesion contained RPc (18/37 disagreed) than when it did not (8/50) disagreed, P = 0.0023). This was not true for oestrogen receptor. In those remaining receptor positive there was only a weak correlation between the first and second values (Spearman rank correlation coefficient, rho = 0.39 for REc, P less than 0.02, and 0.45 for RPc, 0.05 less than P less than 0.1). Receptor levels and receptor status may change with time. Biopsy is most appropriate at the time when systemic treatment is proposed.

Full text

PDF
511

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Allegra J. C., Barlock A., Huff K. K., Lippman M. E. Changes in multiple or sequential estrogen receptor determinations in breast cancer. Cancer. 1980 Feb 15;45(4):792–794. doi: 10.1002/1097-0142(19800215)45:4<792::aid-cncr2820450430>3.0.co;2-x. [DOI] [PubMed] [Google Scholar]
  2. Bloom N. D., Tobin E. H., Schreibman B., Degenshein G. A. The role of progesterone receptors in the management of advanced breast cancer. Cancer. 1980 Jun 15;45(12):2992–2997. doi: 10.1002/1097-0142(19800615)45:12<2992::aid-cncr2820451218>3.0.co;2-d. [DOI] [PubMed] [Google Scholar]
  3. Brennan M. J., Donegan W. L., Appleby D. E. The variability of estrogen receptors in metastatic breast cancer. Am J Surg. 1979 Feb;137(2):260–262. doi: 10.1016/0002-9610(79)90159-4. [DOI] [PubMed] [Google Scholar]
  4. Campbell F. C., Blamey R. W., Elston C. W., Nicholson R. I., Griffiths K., Haybittle J. L. Oestrogen-receptor status and sites of metastasis in breast cancer. Br J Cancer. 1981 Sep;44(3):456–459. doi: 10.1038/bjc.1981.205. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Degenshein G. A., Bloom N., Tobin E. The value of progesterone receptor assays in the management of advanced breast cancer. Cancer. 1980 Dec 15;46(12 Suppl):2789–2793. doi: 10.1002/1097-0142(19801215)46:12+<2789::aid-cncr2820461409>3.0.co;2-k. [DOI] [PubMed] [Google Scholar]
  6. King R. J. Analysis of estradiol and progesterone receptors in early and advanced breast tumors. Cancer. 1980 Dec 15;46(12 Suppl):2818–2821. doi: 10.1002/1097-0142(19801215)46:12+<2818::aid-cncr2820461416>3.0.co;2-z. [DOI] [PubMed] [Google Scholar]
  7. Koenders A., Beex L., Smals A., Kloppenborg P., Benraad T. Oestradiol and progesterone receptors in multiple tumour specimens from patients with breast cancer. Neth J Med. 1980;23(2):62–67. [PubMed] [Google Scholar]
  8. Leake R. E., Laing L., Calman K. C., Macbeth F. R., Crawford D., Smith D. C. Oestrogen-receptor status and endocrine therapy of breast cancer: response rates and status stability. Br J Cancer. 1981 Jan;43(1):59–66. doi: 10.1038/bjc.1981.8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Lippman M. E., Allegra J. C. Quantitative estrogen receptor analyses: the response to endocrine and cytotoxic chemotherapy in human breast cancer and the disease-free interval. Cancer. 1980 Dec 15;46(12 Suppl):2829–2834. doi: 10.1002/1097-0142(19801215)46:12+<2829::aid-cncr2820461419>3.0.co;2-m. [DOI] [PubMed] [Google Scholar]
  10. MacFarlane J. K., Fleiszer D., Fazekas A. G. Studies on estrogen receptors and regression in human breast cancer. Cancer. 1980 Jun 15;45(12):2998–3003. doi: 10.1002/1097-0142(19800615)45:12<2998::aid-cncr2820451220>3.0.co;2-i. [DOI] [PubMed] [Google Scholar]
  11. Moseley H. S., Peetz M. E., Keenan E. J., Awrich A. E., Fletcher W. S. Endocrine ablation for metastatic breast cancer: a reappraisal of hormone receptors. Am J Surg. 1980 Jul;140(1):164–172. doi: 10.1016/0002-9610(80)90435-3. [DOI] [PubMed] [Google Scholar]
  12. Osborne C. K., Yochmowitz M. G., Knight W. A., 3rd, McGuire W. L. The value of estrogen and progesterone receptors in the treatment of breast cancer. Cancer. 1980 Dec 15;46(12 Suppl):2884–2888. doi: 10.1002/1097-0142(19801215)46:12+<2884::aid-cncr2820461429>3.0.co;2-u. [DOI] [PubMed] [Google Scholar]
  13. Paridaens R., Sylvester R. J., Ferrazzi E., Legros N., Leclercq G., Heuson J. C. Clinical significance of the quantitative assessment of estrogen receptors in advanced breast cancer. Cancer. 1980 Dec 15;46(12 Suppl):2889–2895. doi: 10.1002/1097-0142(19801215)46:12+<2889::aid-cncr2820461430>3.0.co;2-4. [DOI] [PubMed] [Google Scholar]
  14. Rosen P. P., Menendez-Botet C. J., Urban J. A., Fracchia A., Schwartz M. K. Estrogen receptor protein (ERP) in multiple tumor specimens from individual patients with breast cancer. Cancer. 1977 May;39(5):2194–2200. doi: 10.1002/1097-0142(197705)39:5<2194::aid-cncr2820390537>3.0.co;2-y. [DOI] [PubMed] [Google Scholar]
  15. Webster D. J., Bronn D. G., Minton J. P. Estrogen receptor levels in multiple biopsies from patients with breast cancer. Am J Surg. 1978 Sep;136(3):337–338. doi: 10.1016/0002-9610(78)90289-1. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES